Last updated: September 24, 2026
Sunmark All Day Allergy-D is an OTC combination product built around cetirizine hydrochloride, an H1 antihistamine, and pseudoephedrine hydrochloride, a nasal decongestant. Its commercial value depends less on active-ingredient exclusivity than on reliable extended-release performance, low-cost tablet manufacture, retailer access, pseudoephedrine compliance, and differentiated packaging.
The main formulation opportunity is to optimize pseudoephedrine release while preserving rapid cetirizine availability. The principal risks are dose-dumping, tablet robustness, moisture sensitivity, regulatory controls on pseudoephedrine, and substitution by single-ingredient cetirizine or newer allergy products.
What active ingredients and dosage forms does Sunmark All Day Allergy-D contain?
Sunmark All Day Allergy-D is marketed as an oral extended-release tablet containing cetirizine hydrochloride and pseudoephedrine hydrochloride. The product family may include 12-hour and 24-hour strengths, depending on the package and market presentation.
| Product configuration |
Cetirizine hydrochloride |
Pseudoephedrine hydrochloride |
Release profile |
| 12-hour configuration |
5 mg |
120 mg |
Extended-release pseudoephedrine |
| 24-hour configuration |
10 mg |
240 mg |
Extended-release pseudoephedrine |
The 12-hour configuration corresponds to the established cetirizine 5 mg/pseudoephedrine 120 mg combination associated with Zyrtec-D 12 Hour. The 24-hour configuration corresponds to the 10 mg/240 mg combination associated with Zyrtec-D 24 Hour. The applicable package label controls the precise strength and directions for a particular Sunmark SKU.[1]
Cetirizine is generally formulated for rapid dissolution. Pseudoephedrine requires controlled release to maintain decongestant exposure over the labeled dosing interval and to limit peak-related adverse effects.
What excipients are strategically important in the formulation?
The precise inactive-ingredient list depends on the manufacturer, dosage strength, tablet design, and private-label supply agreement. From a formulation perspective, the important excipient functions are predictable.
Release-controlling polymers
The core intellectual-property and manufacturing value is likely concentrated in the pseudoephedrine extended-release system rather than in ordinary tablet fillers.
Relevant polymer classes include:
- Hypromellose matrix polymers
- Ethylcellulose or other water-insoluble coating polymers
- Methacrylate copolymers
- Polyvinyl acetate-based controlled-release polymers
- Film-coating systems containing plasticizers and pigments
A hydrophilic matrix can provide low-cost manufacturing through direct compression or dry granulation. A coated-particle or multiparticulate system can offer tighter control of release but generally increases process complexity and analytical burden.
The preferred commercial design depends on target cost, tablet size, dissolution performance, and contract-manufacturing capabilities.
Fillers and compressibility aids
Microcrystalline cellulose, lactose, mannitol, dibasic calcium phosphate, and related fillers can support tablet weight control and mechanical strength. Selection affects:
- Tablet hardness
- Friability
- Disintegration
- Moisture uptake
- Blend uniformity
- Compression speed
- Cost per tablet
A filler system must accommodate the relatively high pseudoephedrine load in the 24-hour configuration. Excessive diluent use increases tablet size, which can reduce consumer acceptability and raise packaging costs.
Binders and granulation aids
Povidone, copovidone, pregelatinized starch, and hydroxypropyl cellulose can improve granule strength and content uniformity. For an extended-release product, binder concentration must be controlled because overbinding can slow release of the cetirizine fraction or interfere with pseudoephedrine dissolution.
Dry granulation may offer a lower-moisture process than wet granulation. That can be commercially attractive where the formulation or coating system is moisture-sensitive.
Lubricants and glidants
Magnesium stearate, stearic acid, colloidal silicon dioxide, and sodium stearyl fumarate are typical process aids. Their levels affect:
- Ejection force
- Tablet capping
- Blend flow
- Coating adhesion
- Dissolution rate
Over-lubrication with hydrophobic magnesium stearate can reduce wettability and produce unacceptable dissolution variability. This risk is more significant when the formulation depends on rapid cetirizine release alongside controlled pseudoephedrine release.
Film coating and colorants
A film coat can improve swallowability, protect the tablet from humidity, mask taste, and provide product identification. Commercially useful coating attributes include:
- Low tack during high-speed coating
- Sufficient abrasion resistance
- Stable color across production lots
- Compatibility with blister and bottle packaging
- Minimal impact on dissolution
A colored film coat also helps distinguish the 12-hour and 24-hour presentations and supports retail shelf recognition.
How should the excipient system be engineered for commercial performance?
The strongest strategy is a dual-release architecture.
Rapid cetirizine release
Cetirizine should become available promptly after oral administration. The excipient system should avoid unnecessary barriers around the antihistamine fraction. Rapid disintegration of the cetirizine portion can support early symptom relief while the pseudoephedrine fraction continues releasing over the labeled interval.
Controlled pseudoephedrine release
Pseudoephedrine may be incorporated in a hydrophilic matrix, coated granules, or a combination system. The development target should include:
- Reproducible release across the full dosing interval
- Limited initial burst
- No clinically meaningful alcohol-triggered dose dumping
- Consistent performance after storage
- Robustness across physiological pH conditions
FDA modified-release guidance emphasizes dissolution testing as a central tool for formulation development, quality control, and postapproval changes.[2]
Tablet size and patient handling
A high-load decongestant tablet can become large, especially in a 24-hour dosage form. Excipients that improve compressibility and reduce tablet weight may create a commercial advantage. A smaller tablet can improve adherence and reduce swallowing complaints, although the product must retain sufficient mechanical strength for automated packaging.
Moisture and packaging
Moisture can alter polymer hydration, tablet hardness, coating integrity, and dissolution. Bottles with induction seals and desiccant systems may provide stronger moisture protection than low-barrier packaging. Unit-dose blister packaging can improve portability and support controlled pharmacy sales of pseudoephedrine products, but it may carry higher packaging costs.
What FDA regulatory status applies to Sunmark All Day Allergy-D?
Sunmark All Day Allergy-D is an OTC drug product using active ingredients and labeling associated with the FDA OTC monograph framework for internal analgesic, antipyretic, and antirheumatic drug products and related OTC categories, subject to the applicable regulatory pathway and product-specific labeling.[3]
The product is not a biologic and does not face biosimilar substitution risk. It is also not generally treated like a new prescription drug with a conventional new-drug exclusivity period. The commercial and regulatory analysis instead centers on:
- Compliance with the applicable OTC monograph or approved application
- Active-ingredient dosage and labeling
- Extended-release dissolution
- Manufacturing controls
- Adverse-event reporting
- Pseudoephedrine sales controls
- State and federal pharmacy requirements
FDA’s OTC monograph reforms under the CARES Act changed the procedural framework for many nonprescription products, but they did not create a conventional patent-based exclusivity period for a private-label cetirizine/pseudoephedrine product.[3]
What is the Orange Book status of Sunmark All Day Allergy-D?
Sunmark All Day Allergy-D does not have the typical Orange Book patent profile associated with a prescription drug approved under an NDA. OTC private-label products generally do not generate a meaningful Orange Book patent barrier unless the product is marketed under an approved NDA with listed patents or exclusivity.
The practical result is:
| Exclusivity category |
Relevance to Sunmark All Day Allergy-D |
| New chemical entity exclusivity |
Not applicable to cetirizine or pseudoephedrine |
| Five-year NDA exclusivity |
Not ordinarily applicable to the private-label OTC product |
| Three-year clinical investigation exclusivity |
Not ordinarily applicable |
| Pediatric exclusivity |
No known product-specific role |
| Orphan-drug exclusivity |
Not applicable |
| Biosimilar exclusivity |
Not applicable |
| Orange Book patent listing |
No conventional private-label barrier expected |
| OTC monograph protection |
Regulatory compliance pathway, not market exclusivity |
When does Sunmark All Day Allergy-D lose exclusivity?
Sunmark All Day Allergy-D does not have a conventional product-specific patent expiration date that determines generic entry. Cetirizine and pseudoephedrine are long-established active ingredients, and multiple manufacturers can market compliant alternatives.
The relevant competitive timetable is driven by:
- Supplier and contract-manufacturing arrangements.
- Retailer category resets.
- Pseudoephedrine purchasing restrictions.
- FDA compliance and enforcement.
- Formulation cost and dissolution performance.
- Private-label procurement cycles.
A competitor does not generally need to wait for a Sunmark patent expiration to introduce a compliant equivalent. It must satisfy the applicable OTC regulatory requirements and avoid infringement of any valid formulation or manufacturing patents held by third parties.
What patent litigation and Paragraph IV risks affect the product?
A Paragraph IV certification is principally associated with an abbreviated new drug application referencing an NDA-listed drug. It is not the normal competitive mechanism for an OTC monograph product.
Potential patent exposure could still arise from:
- Controlled-release polymer systems
- Coated pseudoephedrine particles
- Multiparticulate delivery technologies
- Manufacturing processes
- Specific excipient ratios
- Abuse-deterrent or tamper-resistant systems
- Packaging or dispensing technologies
These patents would need to be assessed through a separate freedom-to-operate review. They would not automatically create a Sunmark-specific exclusivity period.
No product-specific litigation or settlement agreement can be inferred from the Sunmark brand name alone. Private-label OTC arrangements are often governed by supply, quality, indemnity, and regulatory-compliance agreements rather than public patent settlements.
What commercial opportunities exist for the excipient strategy?
Lower-cost private-label substitution
The largest opportunity is cost reduction against branded cetirizine/pseudoephedrine products such as Zyrtec-D. A manufacturer that reproduces the target dissolution profile with a simpler matrix formulation can compete on retailer margin and shelf price.
24-hour convenience
A 24-hour formulation can command stronger consumer preference than a 12-hour product when the price premium is limited. Excipient optimization that reduces tablet size or improves swallowability can support this positioning.
Retailer-exclusive products
Pharmacy chains, wholesalers, and mass retailers can use the same active-ingredient platform for multiple store brands. The supplier can gain scale by standardizing:
- Active-ingredient sourcing
- Tablet tooling
- Coating equipment
- Bottle and blister formats
- Stability protocols
- Dissolution methods
Seasonal inventory flexibility
Allergy and cold products have seasonal demand. A formulation with stable release characteristics and long shelf life can reduce inventory write-offs and support pre-season stocking.
Packaging innovation
Pseudoephedrine products are subject to regulated sales processes. Unit-dose packaging, pharmacist-controlled dispensing, tamper-evident seals, and inventory tracking can create value even where the tablet itself is not patent protected.
Adjacent line extensions
A platform could support related products such as:
- Cetirizine-only tablets
- Pseudoephedrine-only extended-release tablets
- 12-hour and 24-hour combinations
- Seasonal allergy multipacks
- Non-drowsy allergy positioning
- Pediatric products where permitted by labeling and formulation data
The principal constraint is that line extensions must retain compliant labeling and avoid creating unsupported efficacy claims.
How strong is the patent estate for Sunmark All Day Allergy-D?
The product-specific patent estate is likely weak as a barrier to entry because the active ingredients are mature and the product is an OTC combination. The stronger protection lies in execution:
| Asset |
Strategic strength |
| Active ingredients |
Low patent differentiation |
| Combination concept |
Low to moderate, depending on claims |
| Extended-release formulation |
Moderate if supported by enforceable claims |
| Manufacturing process |
Moderate where process-specific and difficult to design around |
| Retail distribution |
High practical value |
| Pseudoephedrine compliance infrastructure |
Moderate to high operational value |
| Brand recognition |
Dependent on retailer and consumer exposure |
| Formulation know-how |
Moderate, particularly for dissolution and scale-up |
A competitor can usually design around a formulation patent by changing polymer grade, coating weight, granulation method, or release architecture. The most defensible position would combine narrow formulation claims with difficult-to-reproduce process controls and strong retailer contracts.
How does Sunmark All Day Allergy-D compare with branded Zyrtec-D?
| Factor |
Sunmark All Day Allergy-D |
Zyrtec-D |
| Brand owner |
Private-label or retailer-associated brand |
Johnson & Johnson consumer-health heritage |
| Active ingredients |
Cetirizine plus pseudoephedrine |
Cetirizine plus pseudoephedrine |
| Main differentiation |
Price and retail availability |
Brand recognition and consumer trust |
| Patent leverage |
Limited product-specific leverage expected |
Historical formulation and brand-related assets may exist |
| Retail position |
Strong where retailer controls shelf space |
Stronger national brand recognition |
| Substitution risk |
High |
High from store brands and generic equivalents |
| Regulatory risk |
OTC compliance and pseudoephedrine controls |
Same core regulatory constraints |
| Commercial moat |
Procurement and distribution |
Brand, distribution, and marketing |
Sunmark’s opportunity is greatest where the retailer prioritizes gross margin and private-label penetration. Zyrtec-D retains an advantage in branded demand and consumer familiarity, but its active-ingredient platform is readily substitutable.
What generic launch scenarios exist?
Three launch scenarios are commercially realistic.
- Low-cost 12-hour tablet: Competes on price and broad pharmacy availability. This is the simplest entry route.
- 24-hour premium private label: Uses a smaller, more robust tablet and emphasizes once-daily convenience.
- Retailer-controlled seasonal platform: Combines several allergy products under one private-label family and uses coordinated packaging and promotions.
The fastest route is usually a conventional extended-release tablet using established excipient systems. A multiparticulate product may offer stronger performance differentiation but can increase manufacturing cost and regulatory complexity.
Key Takeaways
- Sunmark All Day Allergy-D is an OTC cetirizine/pseudoephedrine extended-release product family.
- The principal formulation challenge is rapid cetirizine availability combined with controlled pseudoephedrine release.
- Excipients with the greatest commercial value are release-controlling polymers, compressibility aids, lubricants, film-coating systems, and moisture-protection components.
- The product does not have a conventional NDA-style exclusivity period or obvious Orange Book barrier.
- Paragraph IV litigation is not the normal competitive pathway for this OTC private-label product.
- Commercial strength depends on cost, retailer access, pseudoephedrine compliance, tablet size, dissolution consistency, and seasonal inventory execution.
- The best opportunity is a scalable private-label platform supporting 12-hour and 24-hour allergy-decongestant products.
- Formulation patents may create targeted barriers, but mature active ingredients and established OTC technology make design-around risk substantial.
FAQs
Can Sunmark All Day Allergy-D use the same excipients as Zyrtec-D?
It can use functionally similar excipient systems, but it does not need to use the same formulation. A private-label manufacturer can develop a different matrix, coating, or granulation process if the product meets applicable quality and dissolution requirements and avoids third-party patent infringement.
Is pseudoephedrine the main commercial constraint?
Yes. Federal and state controls on pseudoephedrine sales create more operational complexity than cetirizine sourcing. Retailers must manage purchase limits, identification requirements, transaction records, inventory controls, and pharmacy procedures.[4]
Does an excipient change create a new OTC exclusivity period?
Generally, no. An excipient change does not create a new chemical-entity exclusivity period. It may require regulatory documentation, stability data, dissolution data, or an application-specific assessment, but it does not automatically establish market exclusivity.
Can a manufacturer sell a cetirizine-pseudoephedrine product without a Paragraph IV filing?
Yes, where the product is marketed through the applicable OTC regulatory pathway rather than as an ANDA referencing an Orange Book-listed NDA. The manufacturer still must satisfy FDA requirements and conduct a separate patent clearance review.
Which excipients create the greatest manufacturing risk?
Release-controlling polymers and lubricants typically create the greatest risk because small changes in grade, particle size, concentration, mixing time, or coating weight can alter dissolution. Moisture-sensitive formulations add stability and packaging risk.
References
- U.S. Food and Drug Administration. (n.d.). DailyMed: Cetirizine hydrochloride and pseudoephedrine hydrochloride extended-release labeling. National Library of Medicine.
- U.S. Food and Drug Administration. (1997). Guidance for industry: Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations.
- U.S. Food and Drug Administration. (2023). Nonprescription drug products and the Over-the-Counter Monograph Reform provisions.
- U.S. Drug Enforcement Administration. (n.d.). Pseudoephedrine and the Combat Methamphetamine Epidemic Act requirements.
